Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors

NCT06238401 is registered in ClinicalTrials.gov with Hangzhou Adcoris Biopharmacy Co., Ltd as lead sponsor.

NCT NCT06238401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06238401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
Lead sponsor
Hangzhou Adcoris Biopharmacy Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
October 29, 2024
Completion date
November 30, 2026
Enrollment
77 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors